Selumetinib Activity in Thyroid Cancer Cells: Modulation of Sodium Iodide Symporter and Associated miRNAs

Background: The MEK (mitogen-activated protein kinase)–inhibitor selumetinib led to increased radioiodine uptake and retention in a subgroup of patients suffering from radioiodine refractory differentiated thyroid cancer (RR-DTC). We aimed to analyse the effect of selumetinib on the expression of so...

Descripción completa

Detalles Bibliográficos
Autores principales: Wächter, Sabine, Wunderlich, Annette, Greene, Brandon H., Roth, Silvia, Elxnat, Moritz, Fellinger, Sebastian A., Verburg, Frederik A., Luster, Markus, Bartsch, Detlef K., Di Fazio, Pietro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073679/
https://www.ncbi.nlm.nih.gov/pubmed/30018229
http://dx.doi.org/10.3390/ijms19072077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073679/
https://www.ncbi.nlm.nih.gov/pubmed/30018229
http://dx.doi.org/10.3390/ijms19072077

Ejemplares similares